Clinical Appraisal of Drugs

Phenethyldiguanide: A Dangerous Sideeffect

“…fall into two groups-gastrointestinal and metabolic. The gastro-intestinal upsets, while troublesome in earlier studies, can be reduced in frequency by slow increase of dosage (Pomeranze, 1958;Walker, 1959). Metabolic upset has been indicated by the occurrence of acidosis and ketonuria in the presence of normoglycaemia or mild hyperglycaemia (Hall et al, 1958;Steiner and Williams, 1959).…”

“…has a place in the treatment of adult diabetics, in whom it has an advantage over the arylsulphonylureas by reason of the absence of secondary failures and a wider spectrum of action Krall and Camerini-Davalos, 1958;Walker, 1959). In addition, it may in conjunction with insulin improve the control of unstable diabetics (Pomeranze, 1957;Odell et al, 1958;Krall and Bradley, 1959). The action of D.B.I.…”

Oral Hypoglycæmic Agents in the Treatment of Diabetes Mellitus

“…Phenethyldiguanide (D.B.I.) is a potent hypoglycemic drug, whether or not there is an intrinsic source of insulin: accordingly it has been claimed to have a place in the treatment of all types of diabetes (Steiner and Williams, 1959;Pomeranze et al, 1959). This paper is a report of our experiences with 109 patients in two years.…”

Effect of Phenethylbiguanide on Adrenal Function and Responsiveness as Measured by ACTH Test.

“…DBI has been used by Pomeranze( 5,6), Williams, et aZ. Unger, Freedman and Shapiro (4), reviewing a group of potentially hypoglycemic drugs, discovered N B' Phenethylformadinylimourea (DBI) t, a biguanide.…”

“…Armstrong and McMillan ( 6), and Armstrong, McMillan and Shaw acid (MOMA) as a product of noradrenaline metabolism in humans. After intravenous infusion of adrenaline only 1 to 3% of the amount infused can be recovered in the urine as adrenaline or a conjugate of adrenaline ( 1,2,3) .…”